Moreover, a reduction in Foxj2 levels was observed during the pathological processes of numerous diseases characterized by inflammation, including high‐fat diet (HFD)–induced obesity, HFD‐induced nonalcoholic fatty liver disease (NAFLD), doxorubicin‐induced cardiomyopathy, acute myocardial infarction (AMI) and D‐galactose induced aging conditions. Here, FOXJ2 is linked to metabolic dysfunction-associated steatotic liver disease.